Trial · NCT00139737
Extension Study: Evaluating the Safety of Oral Ziprasidone in the Treatment of Subjects With Schizophrenia
NCT00139737, Phase 3, Completed, Pfizer's Upjohn has merged with Mylan to form Viatris Inc.; results first posted 2010-07-14
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Extension Study: Evaluating the Safety of Oral Ziprasidone in the Treatment of Subjects With Schizophrenia. Trials, record NCT00139737. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00139737
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Extension Study: Evaluating the Safety of Oral Ziprasidone in the Treatment of Subjects With Schizophrenia
- NCT number
- NCT00139737
- Status
- Completed
- Phases
- Phase 3
- Enrollment
- 344 participants, actual
- Lead sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
- Conditions
- Schizophrenia
- Interventions
- Ziprasidone
- First posted
- 2005-08-31
- Last updated
- 2021-03-03
- Results first posted
- 2010-07-14
Source ClinicalTrials.gov
Registered outcomes1
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) | Baseline up to 72 months | All observed or volunteered treatment-emergent AEs and SAEs regardless of treatment group or suspected causal relationship to the investigational product were reported. |
Source ClinicalTrials.gov
Outcomes1
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) | Baseline up to 72 months | Safety Analysis Set = All subjects who took at least 1 dose of study drug | Participants | NUMBER |
Source ClinicalTrials.gov
Results by group2
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) | Ziprasidone | AEs | 177 | Participants | |
| Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) | Ziprasidone | SAEs | 32 | Participants |
Source ClinicalTrials.gov
Participant flow4
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Ziprasidone | 344 | |
| Overall Study | Received Treatment | Ziprasidone | 331 | |
| Overall Study | COMPLETED | Ziprasidone | 3 | |
| Overall Study | NOT COMPLETED | Ziprasidone | 341 |
Source ClinicalTrials.gov
Adverse events162
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Arrhythmia | Cardiac disorders | Ziprasidone | 1 | 331 | |
| other | Bundle branch block right | Cardiac disorders | Ziprasidone | 2 | 331 | |
| other | Conduction disorder | Cardiac disorders | Ziprasidone | 1 | 331 | |
| other | Extrasystoles | Cardiac disorders | Ziprasidone | 1 | 331 | |
| other | Myocardial ischaemia | Cardiac disorders | Ziprasidone | 1 | 331 | |
| other | Sinus tachycardia | Cardiac disorders | Ziprasidone | 2 | 331 | |
| other | Tachycardia | Cardiac disorders | Ziprasidone | 2 | 331 | |
| other | Goitre | Endocrine disorders | Ziprasidone | 1 | 331 | |
| other | Hyperprolactinaemia | Endocrine disorders | Ziprasidone | 5 | 331 | |
| other | Hyperthyroidism | Endocrine disorders | Ziprasidone | 1 | 331 |
1 to 10 of 162Source ClinicalTrials.gov
See all 162 adverse eventsAdverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Ziprasidone | ||
| Total, other adverse events | Ziprasidone | 177 | 331 |
| Total, serious adverse events | Ziprasidone | 32 | 331 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00139737
GET https://conductscience.org/api/trials/v1/NCT00139737/events?page=2